Christoph Mann

Christoph Mann

Philipps Universität Marburg - Marburg / Germany
Medical and Health Sciences / Hematology
AD Scientific Index ID: 5937393
Philipps University of Marburg
person_outline Christoph Mann's MOST POPULAR ARTICLES
1-) Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG …H Goldschmidt, EK Mai, U Bertsch, R Fenk, E Nievergall, D Tichy, ...The Lancet Haematology 9 (11), e810-e821, 2022662022
2-) Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: interim analysis of the GMMG-CONCEPT trialLB Leypoldt, B Besemer, AM Asemissen, M Hänel, IW Blau, M Görner, ...Leukemia 36 (3), 885-888, 2022572022
3-) Isatuximab, carfilzomib, lenalidomide, and dexamethasone for the treatment of high-risk newly diagnosed multiple myelomaLB Leypoldt, D Tichy, B Besemer, M Hänel, MS Raab, C Mann, M Munder, ...Journal of Clinical Oncology 42 (1), 26-37, 2024332024
4-) Addition of isatuximab to lenalidomide, bortezomib and dexamethasone as induction therapy for newly-diagnosed, transplant-eligible multiple myeloma patients: the phase III GMMG …H Goldschmidt, EK Mai, E Nievergall, R Fenk, U Bertsch, D Tichy, ...Blood 138, 463, 2021322021
5-) Depth of response to isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: Interim analysis of the GMMG …K Weisel, AM Asemissen, B Besemer, M Haenel, IW Blau, M Goerner, ...Journal of Clinical Oncology 38 (15_suppl), 8508-8508, 2020312020